Back to news

Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)

Globe Newswire•19/11/2026•07:00 ET
0

Key Highlights

  • ➤Regeneron will present 14 hematology abstracts at ASH 2026
  • ➤Ordspono primary ELM-2 results target relapsed/refractory marginal zone lymphoma
  • ➤Lynozyfic longer-term LINKER-AL2 data covers relapsed/refractory systemic AL amyloidosis
  • ➤Cemdi-poze PNH analysis compares LDH normalization and transfusion avoidance with ravulizumab
  • ➤Pipeline includes investigational siRNA therapies for PNH, aplastic anemia and beta-thalassemia

Expert Statements

L. Andres Sirulnik, Senior Vice President and Hematology Clinical Development Unit Head at Regeneron

“At ASH, we are sharing new and updated data from our broad clinical development programs for Ordspono and Lynozyfic, showcasing their potential to provide meaningful efficacy for patients across a broad spectrum of lymphoma and multiple myeloma settings. For our CD20xCD3 bispecific antibody Ordspono, we are presenting potentially pivotal, first-in-class data in patients with relapsed or refractory marginal zone lymphoma, a disease where patients are eagerly awaiting new options. We are also presenting longer-term results for our BCMAxCD3 bispecific antibody, Lynozyfic, as a second-line treatment for patients with systemic light chain amyloidosis, building on the unprecedented efficacy in this trial previously shared. Additionally, we are eager to share early clinical research for our novel siRNA therapies in blood disorders.”

Primary analysis from a potentially pivotal trial of Ordspono(®) (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development program evaluating Ordspono across a broad spectrum of lymphoma settings

New data on Lynozyfic(®) (linvoseltamab) in R/R systemic light chain (AL) amyloidosis also to be shared in an oral presentation, also part of a clinical development program evaluating Lynzoyfic across a broad spectrum of multiple myeloma settings and precursor conditions

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in